The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

Griffith, Bartley P.; Anderson, Mark; Samuels, Louis E.; Pae, Walter E.; Naka, Yoshifumi; Frazier, O. H.

doi:10.1016/j.jtcvs.2012.01.067

Cited by 193 publications

(99 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Instead, short-term ventricular assist devices (VADs), which generally consist of internal cannulae and an external pump, have been developed for this application and have become a widely accepted treatment option in RCS. [4][5][6][7][8] In addition, there has been a resurgence of interest in veno-arterial extracorporeal membrane oxygenation (VA ECMO), as this approach has become safer and more reliable. [9][10][11][12][13] The bridge-to-transplant or destination therapy devices, as the second-stage treatment, require more durability and reliability, as well as feasibility of outpatient management.…”

mentioning

confidence: 99%

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era

Takayama

Truby

Koekort

et al. 2013

The Journal of Heart and Lung Transplantation

Self Cite

187

104

View full text Add to dashboard Cite

mentioning

confidence: 99%

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era

Takayama

Truby

Koekort

et al. 2013

The Journal of Heart and Lung Transplantation

Self Cite

187

104

View full text Add to dashboard Cite

“…Impella 2.5 (Abiomed, Danvers, MA) is a catheter-mounted microaxial rotary pump capable of displacing 2.5 L of blood per minute, draining blood from the LV, and delivering it to the aortic root using the venturi effect. [12][13][14][15] It has been used to augment the cardiac output and to unload the LV in the setting of cardiogenic and postcardiotomy shock. [12][13][14][15] Use of the Impella in the adult population as a short-term bridge to long-term mechanical support has also been described.…”

mentioning

confidence: 99%

“…[12][13][14][15] It has been used to augment the cardiac output and to unload the LV in the setting of cardiogenic and postcardiotomy shock. [12][13][14][15] Use of the Impella in the adult population as a short-term bridge to long-term mechanical support has also been described. 15,16 We present our experience with the Impella 2.5 (Abiomed) as an adjunct for aggressive LV unloading during femoral VA ECMO support before implantation of a HeartMate II (Pleasanton, CA) long-term VAD.…”

mentioning

confidence: 99%

Impella to Unload the Left Ventricle During Peripheral Extracorporeal Membrane Oxygenation

Cheng

Swartz²,

Massey³

2013

ASAIO Journal

130

View full text Add to dashboard Cite

Peripheral venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute cardiac failure reestablishes normal oxygen delivery and perfusion. However, VA ECMO can be limited by insufficient ventricular unloading, resulting in thrombus formation and pulmonary edema. Impella 2.5 has been used to unload the left ventricle and provide hemodynamic support during acute heart failure. We present our experience of the Impella 2.5 as an adjunct for left ventricular unloading during peripheral VA ECMO support and as a bridge for the HeartMate II left ventricular assist device (LVAD). An Impella 2.5 was placed in patients who were on peripheral VA ECMO with evidence of left ventricular distension. Patients who were candidates for heart transplant were transitioned to the HeartMate II LVAD. Five patients on VA ECMO with ventricular distension underwent Impella 2.5 implantation, resulting in a decreased left ventricular end-diastolic diameter as measured by echocardiography (7.8 ± 1.4 vs. 6.2 ± 0.8 cm, p = 0.001). Four patients were subsequently transitioned to the HeartMate II LVAD after restoration of end-organ function. Impella 2.5 is a safe means to unload the left ventricle while on peripheral VA ECMO to prevent left ventricle thrombus formation and worsening pulmonary edema in patients transitioning to a HeartMate II LVAD.

show abstract

“…LVADs enhance total cardiac output by adding to that of the damaged native heart, potentially allowing myocardial recovery, particularly in patients with cardiogenic shock [30][31][32][33][34].…”

Section: The Effectiveness Of Lvad Was Assessed In the Randomized Evamentioning

confidence: 99%

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Yurevich¹,

Borer²

2017

The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure

View full text Add to dashboard Cite

Though heart failure therapies, particularly for systolic heart failure, have developed rapidly and markedly during the past four decades, a need for additional relief persists and is progressively being met. Two new drugs have been approved for marketing in the United States within the past two years, and two other glucose lowering therapies for diabetes appear to have efficacy for heart failure as well. In addition, device therapy for heart failure has progressed markedly during the past 5 years, particularly in refinements of the indications and applications of devices to minimize symptoms and hospitalizations and to maximize survival. This chapter will outline these recent developments.

show abstract

The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

Abstract: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.

Cited by 193 publications

References 24 publications

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era

Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era

Impella to Unload the Left Ventricle During Peripheral Extracorporeal Membrane Oxygenation

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Contact Info

Product

Resources

About